High-Impact Neuromedicines for Real-World Care
New York, NY
Joined January 2020
- Tweets134
- Following43
- Followers91
- Likes8
Meet Ellen Nowakowski, Senior Director, New Product Planning, and our latest #LBBold spotlight. To Ellen, being bold means challenging the status quo, exploring new ways of working, and learning from the perspectives around her. Learn more about our team: bit.ly/4z0yu9O
Lead. Live. Boldly.
We are excited to introduce LB’s new look, including our updated website that reflects our commitment to developing high-impact neuromedicines for real-world care.
Explore our new website: lbpharma.com/
Members of our executive team will participate in multiple upcoming investor conferences.
Read our press release for more details: bit.ly/4sr76Q9
Tune in to the latest episode of the BioTech Nation to hear our CEO, Heather Turner, talk with host Moira Gunn about the clinical development of our investigational small molecule, LB-102, in schizophrenia and other neuropsychiatric disorders: bit.ly/4B7nLvE
Today is #WorldMentalHealthDay. This year’s theme from @WHO, “Lived Experiences Heard: Real Voices, Real Change,” is a powerful reminder to listen to the people at the center of mental health care. Learn more about the 2026 World Mental Health Day theme: bit.ly/4y1LZ7O
At @ECNPtweets’ #ECNP2026, we shared new data which strengthen the scientific rationale for the development of LB-102, our investigational oral small molecule, in mood disorders. Read our press release and view the poster on our website: bit.ly/4rULtqW
Our CEO Heather Turner recently joined Andrea Johnston for an episode of the Fuel For Female Founders podcast. They discussed Heather’s career progression to becoming CEO of a public biotech company and her approach to building strong teams. Watch here: bit.ly/4zcnp5d
Join us for an in-person and virtual R&D Day on October 27. We’ll discuss the mechanism of action for LB-102, our once-daily, orally administered investigational small molecule, as well as NOVA-2, its pivotal Phase 3 trial in schizophrenia. Register here: bit.ly/47EJtK0
In August, we tested you on the negative symptoms of schizophrenia. Now we’re asking about the cognitive symptoms. Check out the poll below. Then visit our website to learn more: lbpharma.us/pipeline/
Which of the following is considered a cognitive symptom of schizophrenia?
80%Difficulty concentrating
0%Delusions
0%Lack of motivation
20%Hallucinations
5 votes • Final resultsSusan G. Kozauer, MD, is our new Chief Medical Officer.
She has more than 20 years of experience across every stage of clinical development, including key contributions to the approval of new therapies for neuropsychiatric disorders.
Learn more: bit.ly/4iZ6EFS
We will have a presence at multiple upcoming investor conferences.
✔️ Wells Fargo 21st Annual Healthcare Conference
✔️ H.C. Wainwright 28th Annual Global Investment Conference
✔️ TD Cowen 6th Annual Novel Mechanisms Neuropsychiatry Summit
Learn more: bit.ly/4x1OWF3
Joseph M. Miller has joined our team as Chief Financial Officer.
He has a proven track record in scaling financial and operational infrastructure to drive pipeline progress and growth, commercialization efforts, and long-term value creation.
Learn more: bit.ly/4ybMLzI
In June, we asked our followers about the positive symptoms of schizophrenia. This month, we're focused on negative symptoms. Answer the poll below. To learn more, visit our website: bit.ly/4qcV0bg
Which of the following is considered a negative symptom of schizophrenia?
100%Reduced expression
0%Hallucinations
0%Movement disorder
0%Delusions
2 votes • Final resultsFor our July #LBBold feature, meet George Nomikos, MD, PhD, VP of Clinical Development. To George, being bold means keeping patients at the heart of every decision and translating scientific discoveries into real-world progress. Learn more about our team: bit.ly/44IAYwv
Unmet needs remain in the treatment of bipolar depression. With current treatments, many experience residual symptoms and poor tolerability. Continued research remains important to advancing neuropsychiatric care. Learn more about our work: bit.ly/4qcV0bg
Listen to our CEO, Heather Turner, discuss her career in biotech and our work to develop novel therapies for the treatment of neuropsychiatric diseases with @ldtimmerman of the @timmermanreport on the The Long Run podcast. Linked in the post below!
A Schizophrenia Drug Patients Can Stick With. Heather Turner of LB Pharmaceuticals is the latest guest on The Long Run. Sponsors: @AlphaSenseInc and Dash Bio. timmermanreport.com/2026/07/…
We welcome Christopher Zergebel as SVP of Clinical Operations. Christopher brings 25+ years of global clinical development & operations leadership experience & will help support the execution of LB-102's ongoing & planned clinical programs. Learn more: bit.ly/4wdgt6l
We posted a quick poll to test your knowledge. Cast your vote, then learn more about the different symptom categories associated with schizophrenia and our ongoing research efforts: lbpharma.us/pipeline/
Question: Which of the below is a positive symptom of schizophrenia?
0%Hallucinations
0%Disorganized thinking
0%Delusions
100%All of the above
1 votes • Final resultsWe recently gathered as a team in New York. The opportunity to connect in person strengthened collaboration across our teams and reinforced the shared commitment behind the work we do advancing novel therapies for neuropsychiatric disorders. Learn more: bit.ly/4pMbHcR
We will participate in two upcoming investor conferences, where we’ll join industry leaders, investors, and peers to discuss our work advancing LB-102 as a potential new treatment for neuropsychiatric disorders. Details below and in our press release: bit.ly/4aixZh1